Clin2
NCT07400536Possibly a fitRecruiting

Cadonilimab plus chemo and radiation for advanced cervical cancer

Locally Advanced Cervical Carcinoma

Treatments studied

Part of Cancer, Women’s health & pregnancy clinical trials.

This trial tests a new immunotherapy drug, cadonilimab, combined with standard chemotherapy followed by chemoradiation for locally advanced cervical cancer. The goal is to see if this combination works better than current treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
378 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are a woman between 18 and 70 years old.
  • You have a type of cervical cancer called squamous cell, adenocarcinoma, or adenosquamous carcinoma.
  • Your cancer is stage IIB to IVA (spread within the pelvis but not to distant organs) and you haven't had any treatment yet.
  • You have at least one tumor that can be measured on scans.
  • You are able to walk and do daily activities without help (ECOG 0–1).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06529809Recruiting· Phase 1/Phase 2
Accelerated brachytherapy and chemo for advanced cervical cancer

This trial tests a new way of delivering radiation therapy (brachytherapy) combined with chemotherapy for advanced cervical cancer. The goal is to see if a faster, more intense radiation schedule is safe and effective.

St Louis, Missouri
NCT06391190Recruiting· Phase 1/Phase 2
Chemoradiation plus immunotherapy for advanced cervical cancer

This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.

Shanghai
NCT05817214Recruiting· Phase 2
Immunotherapy plus targeted drug for advanced cervical cancer

This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.

Wuhan, Hubei
NCT06810895Enrolling by invitation
Immunotherapy plus chemo for recurrent cervical cancer

This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.

Wuhan
NCT07649174Not yet recruiting· Phase 2
Cadonilimab with chemotherapy for advanced cervical cancer

This trial tests a combination of cadonilimab (an immune-boosting drug) plus chemotherapy for locally advanced cervical cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.

Shanghai
NCT07450963Not yet recruiting· Phase 2
Cadonilimab plus radiation for cervical cancer patients who cannot get standard chemo

This trial tests a new immunotherapy drug called cadonilimab combined with radiation therapy for people with locally advanced cervical cancer who cannot receive the usual chemotherapy due to age, kidney problems, heart issues, allergies, or personal choice.

Hear when a new Locally Advanced Cervical Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.